Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Sep;116(3):612-618.
doi: 10.1097/AOG.0b013e3181ed36cc.

Titrated oral misoprostol solution compared with intravenous oxytocin for labor augmentation: a randomized controlled trial

Ming Ho  1 , Shi-Yann Cheng, Tsai-Chung Li
Affiliations
Randomized Controlled Trial

Titrated oral misoprostol solution compared with intravenous oxytocin for labor augmentation: a randomized controlled trial

Ming Ho et al. Obstet Gynecol. 2010 Sep.

Abstract

Objective: To compare titrated oral misoprostol to intravenous oxytocin for labor augmentation among women at 36 to 42 weeks of gestation with spontaneous onset of active labor.

Methods: Women meeting the general selection criteria with regular contractions and an effaced cervix dilated between 3 and 9 cm, and who had inadequate uterine contractions (two or fewer contractions every 10 minutes) during the first stage of labor, were randomly assigned to titrated oral misoprostol or intravenous oxytocin. Augmentation-to-vaginal delivery interval and vaginal delivery within 12 or 24 hours were the primary outcomes. The data were analyzed by intention to treat.

Results: Of the 231 women, 118 (51.1%) were randomized to titrated oral misoprostol and 113 (48.9%) to titrated intravenous oxytocin. The median interval from the start of augmentation to vaginal delivery was 5.22 hours (3.77-8.58 hours, 25th-75th percentile) in the misoprostol group, and 5.20 hours (3.23-6.50 hours, 25th-75th percentile) in the intravenous oxytocin group (P=.019). Complete vaginal delivery occurred within 12 hours for 92 women (78.0%) in the misoprostol group and for 97 women (85.8%) in the oxytocin group (P=.121; relative risk 0.91, 95% confidence interval 0.80-1.03). There were no significant differences between the two groups who delivered vaginally within 24 hours. Side effects and neonatal outcomes also did not differ between the two groups.

Conclusion: Labor augmentation with titrated oral misoprostol or intravenous oxytocin resulted in similar rates of vaginal delivery within 12 and 24 hours.

Clinical trial registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00695331.

Level of evidence: I.

PubMed Disclaimer

References

    1. Waldenström U, Hildingsson I, Rubertsson C, Rådestad I. A negative birth experience: prevalence and risk factors in a national sample. Birth 2004;31:17–27.
    1. Nystedt A, Högberg U, Lundman B. Some Swedish women's experiences of prolonged labour. Midwifery 2006;22:56–65.
    1. Florica M, Stephansson O, Nordström L. Indications associated with increased cesarean section rates in a Swedish hospital. Int J Gynaecol Obstet 2006;92:181–5.
    1. Bugg GJ, Stanley E, Baker PN, Taggart MJ, Johnston TA. Outcomes of labours augmented with oxytocin. Eur J Obstet Gynecol Reprod Biol 2006;124:37–41.
    1. McNiven PS, Williams JI, Hodnett E, Kaufman K, Hannah ME. An early labor assessment program: a randomized, controlled trial. Birth 1998;25:5–10.

Publication types

Associated data